Aims: To investigate whether serum amyloid A protein (SAA) and C-reactive protein (CRP) concentrations could be used in the management of fi thalassaemic patients undergoing bone marrow transplantation (BMT). Methods: Serum SAA and CRP concentrations were determined in paired samples from 66 patients with Ii thalassaemia before and after BMT. Serum SAA concentrations were determined by an enzyme linked immunoassay (EIA); serum CRP concentrations were determined by a nephelometric assay. Results: Serum SAA concentrations before transplantation were significantly higher in the group that subsequently rejected the transplant than the group without complications. SAA concentrations increased after BMT in acute graft versus host disease (GvHD) and rejection. No significant increase in SAA or CRP was found in chronic GvHD. Increases in serum in SAA and CRP concentrations were not related to concomitant infection episodes. Conclusions: The different acute phase response in acute GvHD and rejection compared with chronic GvHD suggests that different immunopathogenic mechanisms are responsible.
Increased serum CRP concentrations after bone marrow transplantation (BMT), carried out for haematological disease other than ,B thalassaemia, have been found in patients with bacterial infections or acute graft versus host disease (GvHD) complicated by infections. But conflicting data about serum CRP concentrations have been reported in acute GvHD without infection.'2 In chronic GvHD without infection episodes no increase in serum CRP has been found. ' SAA is a high density lipoprotein associated plasma protein that is mainly produced in the liver in response to stress or inflammation. It is regulated by the action of cytokines such as interleukin-I (IL-1), interleukin-6 (IL-6), and tumour necrosis factor (TNF).45 Extrahepatic expression of SAA has been shown in virtually all tissues and particularly in those with a recognisable macrophage population. 6 The rise in SAA blood concentrations that occurs during acute events is the most intense and rapid of all the acute phase proteins. Little '9 In acute GvHD and rejection episodes SAA and CRP have shown similar increases even though we failed to find a significant increase in SAA in the group that rejected the transplantation as a result of the higher concentrations before bone marrow infusion. The lack of a significant increase in serum SAA and CRP concentrations in chronic GvHD indicates that different immune effector mechanisms are probably at work in acute and in chronic GvHD. In acute GvHD tissue damage is directly caused by cytotoxic T cells specific for host alloantigens, or by soluble mediators like TNFa, released by T cells or macrophages. In chronic GvHD T cells specific for common determinants of MHC class II molecules produce unusual patterns of cytokine production such as IL-4 and interferon gamma. This different pattern of cytokine production may explain the lack ofa significantly increased APP synthesis during chronic GvHD. 20 Acute GvHD and rejection episodes are often associated with infections, and previous reports have indicated that increased serum CRP concentrations are a useful marker of bacterial infections' as no increase was seen in GvHD episodes without infections. Conversely, our study shows that in ,B thalassaemic patients an acute phase response is mounted during acute GvHD and marrow rejection independently of the occurrence of infections. Indeed, in a previous study we could not find any correlation between the occurrence of infections and an increase in serum TNF concentration in GvHD and rejection.'9 This discrepancy could be related to the various immunological abnormalities described in f thalassaemia and mainly ascribed to chronic antigenic stimulation (blood transfusions) and iron overload.2""
In conclusion, our study indicates that SAA and CRP testing in patients undergoing BMT for ,B thalassaemia may be of clinical relevance in the detection and management of immunological complications but it offers no information about the occurrence of infections. The suggestion that SAA may represent a marker for identifying candidates for rejection warrants further clinical and experimental validation.
